Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 629Prostatic Neoplasms 371Neoplasms 307Carcinoma, Non-Small-Cell Lung 215Lung Neoplasms 204Colorectal Neoplasms 176Multiple Myeloma 144Pancreatic Neoplasms 136Leukemia, Myeloid, Acute 128Neoplasm Metastasis 124Brain Neoplasms 117Melanoma 116Ovarian Neoplasms 103Carcinoma, Hepatocellular 102Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 94Colonic Neoplasms 81Stomach Neoplasms 80Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Triple Negative Breast Neoplasms 75Carcinoma, Renal Cell 75Lymphoma 71Leukemia, Lymphocytic, Chronic, B-Cell 68Lymphoma, Non-Hodgkin 67

Interventions

pembrolizumab 1lenvatinib 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Non-squamous Non-small-cell Lung Cancer × Clear all
NCT05258279 2024-08-28

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Juntendo University

Phase 2 Active not recruiting
30 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡